Sağlık Durumları
18 kanıta dayalı takviye araştırması içeren sağlık durumları
Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.
How We Grade Evidence
Her sağlık durumu sayfası, takviye içeriklerini klinik kanıtların gücüne göre sıralar. Her derecenin anlamı şöyledir:
Strong Evidence
Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.
Good Evidence
At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.
Some Evidence
Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.
Very Early Research
In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.
Ulcerative Colitis (UC)
~0.3% in Western countries; peak onset 15-30 years
Gastroesophageal Reflux Disease (GERD)
20-30% in Western populations; 5-10% in Asia
Chronic Constipation
15-20% of adults globally; increases with age; more common in women
Acute Diarrhea
1.7 billion cases of childhood diarrhea globally per year; 525,000 deaths
Antibiotic-Associated Diarrhea (AAD)
5-39% of antibiotic users; varies by antibiotic class
Clostridioides difficile Infection (CDI)
500,000 infections/year in the US; 29,000 deaths
Functional Dyspepsia
10-20% of the general population
Increased Intestinal Permeability (Leaky Gut)
Prevalence uncertain; measurable by lactulose/mannitol ratio test. Common in IBD, celiac disease, alcoholism
Lactose Intolerance
65-70% of global population (varies widely by ethnicity: 5% Northern European to 90% East Asian)
Traveler's Diarrhea
30-70% of travelers to high-risk areas depending on destination
Peptic Ulcer Disease
5-10% lifetime prevalence; declining due to H. pylori treatment
Bloating and Intestinal Gas
15-30% of general population report regular bloating; more common in IBS patients (>75%)
Irritable Bowel Syndrome (IBS)
10-15% of global population; more common in women (2:1 ratio)
Crohn's Disease
~0.3% in Western countries; peak onset 15-35 years
Small Intestinal Bacterial Overgrowth (SIBO)
Estimated 6-15% in healthy population; up to 80% in IBS patients
Helicobacter pylori Infection
~50% of global population infected; higher in developing countries
Gut Dysbiosis
Prevalence not precisely defined; associated with Western diet, antibiotic use, and numerous chronic diseases
Inflammatory Bowel Disease (IBD) — General
~0.5% in Western countries; rising incidence in Asia and South America
FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.